StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Regulus Therapeutics (RGLS) Selloff 'Overdone' - Wedbush
March 12, 2018 11:08 AM
Wedbush analyst Liana Moussatos said the sell-off in Regulus Therapeutics (NASDAQ: RGLS) is overdone. The firm reiterated an ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Regulus Therapeutics (RGLS) PT Raised to $1.37 at BMO Capital, Sees Shares 'Range-Bound'
March 8, 2018 5:52 AM